SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
September 26, 1997
Date of Report (date of earliest event reported)
CHEUNG LABORATORIES, INC.
(Exact name of Registrant as specified in its charter)
Maryland 000-14242 52-1256615
(State or other (Commission File (IRS Employer
jurisdiction of Number) Identification
Incorporation) Number)
10220-I Old Columbia Road
Columbia, Maryland 21045-1705
(Address of principal executive offices)
410-290-5390
(Registrant's telephone number, including area code)
ITEM 5: Other Information
A. PMA-Supplement granted for APA cancer treatment system
On September 26, 1997, Cheung Laboratories, Inc. (the "Company") announced
that the FDA's Center for Devices and Radiological Health had granted
premarket approval (PMA-Supplement) for a design change to the Company's
Microfocus 1000 hyperthermia cancer treatment system to integrate patented
technology using adaptive phase array targeting and nulling. The proprietary
technology, developed by MIT, is expected to significantly improve the ability
of the system to focus heat, which is used in conjunction with radiation in
the treatment of cancer.
B. Link Joins Board of Directors
On October 9, 1997 the Company announced the appointment of Dr. Max Link
to its Board of Directors, filling a vacancy.
Dr. Link, 57, has had an outstanding career in the pharmaceutical and
biotechnology industries. From 1993 to 1994, he served as Chief Executive
Officer of Corange, Ltd., a leading medical diagnostics company recently
acquired by Hoffman-LaRoche for $11.5 billion. From 1971 to 1993, he held
positions of increasing responsibility with Sandoz Pharma AG culminating
with his appointment as Chairman in 1992.
At present, Dr. Link serves on the Boards of Human Genome Sciences, which
is engaged in research and development of novel proprietary pharmaceutical
and diagnostic products based on the discovery and understanding of the
medical utility of genes; Alexion Pharmaceuticals, a development stage
company involved in the research and development of immunoregulatory
compounds; Cell Therapeutics, which discovers, develops and commercializes
small molecule drugs for the treatment of cancer and inflammatory and immune
diseases; Access Pharmaceuticals, which provides drug delivery systems
through the design of polymer drug complexes; Protein Design Laboratories,
which develops human and humanized antibodies; Osiris Therapeutics, a company
that develops products to regenerate connective tissues; Procept, Inc. and
Cytrx Corp.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CHEUNG LABORATORIES, INC.
Dated: October 14, 1997 By \s\ Spencer J. Volk
----------------------------
Name: Spencer J.Volk
Title: President and Chief Executive Officer